DENTSPLY SIRONA Inc. logo

DENTSPLY SIRONA Inc.

XRAY

NASDAQHealthcareMedical - Instruments & Supplies

Previous close

$10.92

+$0.14 · +1.30%

Aug 21, 4:00 PM ET

XRAY company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

47

Fair Value

Momentum

53

Neutral

Sentiment

63

Bullish

Risk resilience

56

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

DENTSPLY SIRONA Inc. develops, manufactures, and markets dental equipment supported by cloud-enabled solutions, dental products, and healthcare consumable products in urology and enterology worldwide. It operates through four segments: Connected Technology Solutions, Essential Dental Solutions, Orthodontic and Implant Solutions, and Wellspect Healthcare. The Connected Technology Solutions segment offers imaging equipment, motorized dental handpieces, treatment centers, and other instruments; and intraoral scanners, 3-D printers, and mills, as well as CEREC, a full-chairside economical restoration of esthetic ceramic dentistry offering. The Essential Dental Solutions segment provides motorized endodontic handpieces, files, sealers, irrigation needles, and other tools for root canal procedures; restorative products; curing light and dental diagnostic systems; ultrasonic scalers and polishers; and dental anesthetics, prophylaxis paste, dental sealants, and impression materials. The Orthodontic and Implant Solutions segment offers SureSmile, a clear aligner solution that includes whitening kits and retainers; VPro, a high frequency vibration technology device; SureSmile Simulator; DS Core platform, which creates 3D visualization of patient outcomes; dental implant products; digital dentures; crown and bridge porcelain products; bone regenerative and restorative solutions; treatment planning software; educational programs; custom abutments; tapered immediate load screws; regenerative bone growth factor; artificial teeth; and precious metal dental alloys. The Wellspect Healthcare segment offers medical devices, including catheters for urinary retention and advanced irrigation systems to help people suffering from chronic or severe constipation. The company was formerly known as DENTSPLY International Inc. and changed its name to DENTSPLY SIRONA Inc. in February 2016. DENTSPLY SIRONA Inc. was founded in 1877 and is headquartered in Charlotte, North Carolina.

Industry
Medical - Instruments & Supplies
Sector
Healthcare
Headquarters
US
CEO
Daniel T. Scavilla
Listed since
Aug 12, 1987
Employees
14,000

Market position

Day range

Current $10.92

52-week range

Current $10.92

Open
$10.84
Previous close
$10.78
Volume
3.31M
0.62× average
Average volume
5.34M
Average daily volume
Market cap
2.19B USD
Beta
0.87
Market reference 1
50-day average
$11.9886
-8.91% below average
200-day average
$11.7409
-6.99% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
4.42B USD
P/E (TTM)
-3.99×
P/B (TTM)
1.61×
P/S (TTM)
0.6×
EV / EBITDA
-96.11×
Earnings yield
-26.24%
Free cash flow yield
4.56%
Dividend yield
2.93%

Profitability & efficiency

Gross margin
49.52%
Operating margin
11.69%
Net margin
-14.99%
Return on equity
-44.63%
Return on assets
-11.01%
Return on invested capital
5.67%

Financial health

Debt / equity
1.71×
Current ratio
1.51×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends63%32%-0%-32%Gross margin, FY2021: 55.47%Gross margin, FY2022: 54.23%Gross margin, FY2023: 52.61%Gross margin, FY2024: 51.62%Gross margin, FY2025: 50.00%Operating margin, FY2021: 14.37%Operating margin, FY2022: -23.89%Operating margin, FY2023: -2.14%Operating margin, FY2024: -23.17%Operating margin, FY2025: 6.85%Net margin, FY2021: 9.71%Net margin, FY2022: -24.22%Net margin, FY2023: -3.33%Net margin, FY2024: -23.99%Net margin, FY2025: -16.25%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 55.47%. Gross margin FY2022 54.23%. Gross margin FY2023 52.61%. Gross margin FY2024 51.62%. Gross margin FY2025 50.00%. Operating margin FY2021 14.37%. Operating margin FY2022 -23.89%. Operating margin FY2023 -2.14%. Operating margin FY2024 -23.17%. Operating margin FY2025 6.85%. Net margin FY2021 9.71%. Net margin FY2022 -24.22%. Net margin FY2023 -3.33%. Net margin FY2024 -23.99%. Net margin FY2025 -16.25%.

Income trends

Revenue

3.68B USD-2.98%

Operating income

252M USD+1.13B USD

Net income

−598M USD+34.29%
Income trends across reported periods4.75B USD2.68B USD604.3M USD−1.47B USDRevenue, FY2021: 4.23B USDRevenue, FY2022: 3.92B USDRevenue, FY2023: 3.97B USDRevenue, FY2024: 3.79B USDRevenue, FY2025: 3.68B USDOperating income, FY2021: 608M USDOperating income, FY2022: −937M USDOperating income, FY2023: −85M USDOperating income, FY2024: −879M USDOperating income, FY2025: 252M USDNet income, FY2021: 411M USDNet income, FY2022: −950M USDNet income, FY2023: −132M USDNet income, FY2024: −910M USDNet income, FY2025: −598M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 4.23B USD. Revenue FY2022 3.92B USD. Revenue FY2023 3.97B USD. Revenue FY2024 3.79B USD. Revenue FY2025 3.68B USD. Operating income FY2021 608M USD. Operating income FY2022 −937M USD. Operating income FY2023 −85M USD. Operating income FY2024 −879M USD. Operating income FY2025 252M USD. Net income FY2021 411M USD. Net income FY2022 −950M USD. Net income FY2023 −132M USD. Net income FY2024 −910M USD. Net income FY2025 −598M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue3.68B USD3.79B USD3.97B USD3.92B USD4.23B USD
Cost of goods sold1.84B USD1.84B USD1.88B USD1.8B USD1.88B USD
Gross profit1.84B USD1.96B USD2.09B USD2.13B USD2.35B USD
Research and development150M USD165M USD184M USD174M USD171M USD
Selling, general, and administrative1.44B USD1.61B USD1.61B USD1.59B USD1.55B USD
Operating expenses1.59B USD2.84B USD2.17B USD3.06B USD1.74B USD
Interest expense88M USD69M USD81M USD65M USD61M USD
Depreciation and amortization352M USD349M USD343M USD328M USD346M USD
Operating income252M USD−879M USD−85M USD−937M USD608M USD
Net income−598M USD−910M USD−132M USD−950M USD411M USD

Company facts updated Aug 24, 2026.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

31 ratings
Strong buy00%
Buy1239%
Hold1858%
Sell13%
Strong sell00%

XRAY peers

ETFs holding XRAY

Funds reporting this stock among their holdings, ordered by reported position size.

Continue in GoAI

Research XRAY

research.disclaimer